Digest Network Come funziona
Network
/
Società
To
Non verificato

Tolerance Bio, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMercato del lavoroSalute

6 comunicati stampa

Guarda tutti i comunicati
28/09/2026
Mercato del lavoro
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Tolerance Bio Licenses Clinical-Stage Anti-IL-33 Monoclonal Antibody from Tanabe Pharma to Expand Thymus-Focused Clinical Pipeline
Fonte
Tolerance Bio, Inc.
Emittente
Business Wire
1.00
0
19/08/2026
Mercato del lavoro
Industria
Oncologia
HIV, AIDS e malattie autoimmuni
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Tolerance Bio Licenses Clinical-Stage Long-Acting Interleukin-7 Therapy Efineptakin Alfa from NeoImmuneTech to Advance Programs Targeting Thymic Function and Immune Resilience
Fonte
Tolerance Bio, Inc.
Emittente
Business Wire
1.00
0
27/10/2025
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Industria
Tolerance Bio’s Implanted iPSC-derived Thymic Organoids Enable In Vivo Positive Selection of Human T cells and Tumor Burden Reduction in Melanoma
Fonte
Tolerance Bio, Inc.
Emittente
Business Wire
1.00
0
08/09/2025
Biotecnologia
Farmaceutica
Salute
Mercato del lavoro
Industria
Tolerance Bio and ZipCode Bio Announce Strategic R&D Collaboration to Advance Targeted Thymus Therapeutics
Fonte
Tolerance Bio, Inc.
Emittente
Business Wire
1.00
0
19/12/2024
Mercato del lavoro
Biotecnologia
Farmaceutica
Salute
Tolerance Bio, Inc. Announces Scientific Advisory Board and Completion of $20.2 Million Seed Round to Advance Thymus-Based Therapies for Immune-Mediated Diseases
Fonte
Tolerance Bio, Inc.
Emittente
Business Wire
1.00
0
15/10/2024
Scienza
HIV, AIDS e malattie autoimmuni
Finanza
Associazioni/Professionisti
Biologia
Biotecnologia
Sanità
Farmaceutica
Salute
Tolerance Bio, Inc. Launches With $17.2 Million in Seed Financing to Advance Thymus-Based Therapies for Immune-Mediated Diseases
Fonte
Tolerance Bio, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0